Cargando…
T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival
Perioperative chemotherapy enhances the survival rates for patients with esophageal and gastric (EG) adenocarcinoma, but not all patients benefit from this additional treatment. Chemotherapeutic agents have been demonstrated to alter the immune cell (IC) composition in the tumor microenvironment. He...
Autores principales: | Christina Svensson, Maria, Lindén, Albin, Nygaard, Jakob, Borg, David, Hedner, Charlotta, Nodin, Björn, Leandersson, Karin, Jirström, Karin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158033/ https://www.ncbi.nlm.nih.gov/pubmed/34104541 http://dx.doi.org/10.1080/2162402X.2021.1921443 |
Ejemplares similares
-
High Infiltration of CD68(+)/CD163(−) Macrophages Is an Adverse Prognostic Factor after Neoadjuvant Chemotherapy in Esophageal and Gastric Adenocarcinoma
por: Svensson, Maria C., et al.
Publicado: (2022) -
Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival
por: Svensson, Maria C., et al.
Publicado: (2019) -
The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma
por: Svensson, Maria C., et al.
Publicado: (2017) -
Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma
por: Borg, David, et al.
Publicado: (2018) -
Tumor-Associated CD68(+), CD163(+), and MARCO(+) Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma
por: Jeremiasen, Martin, et al.
Publicado: (2020)